Art and Science of Laboratory Medicine

Art and Science of Laboratory Medicine

Friday, April 5, 2013

First Point-of-Care DNA Test Submitted for FDA Clearance by Spartan Bioscience

Spartan Bioscience, a point-of-care DNA testing company, has announced that it has submitted a 510(k) pre-market notification application to the FDA requesting regulatory clearance for its Spartan RX CYP2C19 genetic test.
CYP2C19 is an enzyme that metabolizes commonly-prescribed drugs, including antiarrhythmics, proton pump inhibitors, antidepressants, and antiplatelet drugs. About 30% of Caucasians, 40% of Africans, and more than 50% of Asians and Indians carry CYP2C19 gene variants that reduce response to drugs metabolized by CYP2C19.(1,2,3,4)

Read more:
Spartan RX
 






















Source: Spartan RX

Art and Science of Laboratory Medicine

Twitter: LaboratoryEQAS

No comments:

Follow "Art and Science of Laboratory Medicine " on:


https://www.facebook.com/LaboratoryEQAS
https://twitter.com/LaboratoryEQAS
https://plus.google.com/100408138227362094524/posts
http://www.pinterest.com/labmed/medical-laboratory-and-biomedical-science/
http://www.linkedin.com/in/jwahlstedt
http://clinical-laboratory.blogspot.com/feeds/posts/default